Benzinga - by Vandana Singh, Benzinga Editor. BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14, down from...
Investing.com - After a tumultuous year for the biotech sector, BofA Securities sees early positive signs for 2023, outlining a number of biotech stocks in new research that could...
By Sam Boughedda Morgan Stanley analysts said in a research note Tuesday that 26% of biotechnology companies need funding. The firm estimates 93 companies will have one year of...
Investing.com - Here are three things that fell under the radar this week 1. Bitcoin Bulls Squirm as Popular Indicator Flashes 'Sell' Some blame the bitcoin whales....
By Roberta Rampton and Deena Beasley WASHINGTON/LOS ANGELES (Reuters) - U.S. President Donald Trump on Tuesday met with top executives from some of the biggest drugmakers, calling...
By Lewis Krauskopf NEW YORK (Reuters) - Arguing over politics is a Thanksgiving Day tradition, but Donald Trump's presidential election adds a new twist to any bickering at...
By Caroline Valetkevitch NEW YORK (Reuters) - World stock indexes rose on Wednesday with a rebound in biotechnology shares boosting U.S. equities, while oil prices snapped a...
By Liisa Tuhkanen and Sudip Kar-Gupta LONDON (Reuters) - The FTSE 100 slipped on Tuesday, hit by a slight pick-up in inflation and a fall in energy and mining stocks, weighed down...